Advertisement
FOCL vs STXS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOCL is a StrongBuy and STXS is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FOCL’s FA Score shows that 0 FA rating(s) are green whileSTXS’s FA Score has 0 green FA rating(s).
- FOCL’s FA Score: 0 green, 5 red.
- STXS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FOCL’s TA Score shows that 5 TA indicator(s) are bullish while STXS’s TA Score has 5 bullish TA indicator(s).
- FOCL’s TA Score: 5 bullish, 4 bearish.
- STXS’s TA Score: 5 bullish, 3 bearish.
Price Growth
FOCL (@Medical Distributors) experienced а -22.00% price change this week, while STXS (@Pharmaceuticals: Other) price change was +0.72% for the same time period.
The average weekly price growth across all stocks in the @Medical Distributors industry was -10.67%. For the same industry, the average monthly price growth was -14.33%, and the average quarterly price growth was -24.75%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +6.41%. For the same industry, the average monthly price growth was +10.59%, and the average quarterly price growth was +7.31%.
Reported Earning Dates
FOCL is expected to report earnings on Aug 26, 2026.
STXS is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Medical Distributors (-10.67% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
@Pharmaceuticals: Other (+6.41% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| FOCL | STXS | FOCL / STXS | |
| Capitalization | 174M | 138M | 126% |
| EBITDA | -25.53M | -20.58M | 124% |
| Gain YTD | 44.377 | -39.130 | -113% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 74.1M | 31.2M | 238% |
| Total Cash | 15M | 14.6M | 103% |
| Total Debt | 27.8M | 5.28M | 527% |
FOCL | STXS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 51 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 35 | 81 | |
P/E GROWTH RATING 1..100 | 100 | 57 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
STXS's Valuation (89) in the Medical Specialties industry is in the same range as FOCL (98) in the Biotechnology industry. This means that STXS’s stock grew similarly to FOCL’s over the last 12 months.
STXS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as FOCL (100) in the Biotechnology industry. This means that STXS’s stock grew similarly to FOCL’s over the last 12 months.
FOCL's SMR Rating (99) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that FOCL’s stock grew similarly to STXS’s over the last 12 months.
FOCL's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for STXS (81) in the Medical Specialties industry. This means that FOCL’s stock grew somewhat faster than STXS’s over the last 12 months.
STXS's P/E Growth Rating (57) in the Medical Specialties industry is somewhat better than the same rating for FOCL (100) in the Biotechnology industry. This means that STXS’s stock grew somewhat faster than FOCL’s over the last 12 months.
| FOCL | STXS | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 87% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 83% |
| Advances ODDS (%) | 7 days ago 76% | 3 days ago 76% |
| Declines ODDS (%) | 2 days ago 85% | 8 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 86% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 86% |
Advertisement
FOCL and
Correlation & Price change
A.I.dvisor tells us that FOCL and AORT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FOCL and AORT's prices will move in lockstep.
| Ticker / NAME | Correlation To FOCL | 1D Price Change % | ||
|---|---|---|---|---|
| FOCL | 100% | -20.97% | ||
| AORT - FOCL | 29% Poorly correlated | +0.88% | ||
| AVNS - FOCL | 21% Poorly correlated | N/A | ||
| UFPT - FOCL | 20% Poorly correlated | +0.17% | ||
| SENS - FOCL | 20% Poorly correlated | +0.76% | ||
| STXS - FOCL | 16% Poorly correlated | -4.11% | ||
More | ||||
STXS and
Correlation & Price change
A.I.dvisor indicates that over the last year, STXS has been loosely correlated with SMTI. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then SMTI could also see price increases.
| Ticker / NAME | Correlation To STXS | 1D Price Change % | ||
|---|---|---|---|---|
| STXS | 100% | -4.11% | ||
| SMTI - STXS | 38% Loosely correlated | -0.15% | ||
| TWST - STXS | 36% Loosely correlated | +1.70% | ||
| CERS - STXS | 35% Loosely correlated | +5.65% | ||
| BLFS - STXS | 35% Loosely correlated | +0.43% | ||
| RGEN - STXS | 33% Loosely correlated | +0.56% | ||
More | ||||